CRISPR Therapeutics (CRSP) Q3 2026 Earnings
Includes acquired in-process R&D expense of $11.7 million, primarily a development milestone under the Sirius Agreement
How Did CRSP Stock React to Q3 2026 Earnings?
Did CRSP Beat Earnings? Q3 2026 Results
No. CRISPR Therapeutics reported Q3 2026 earnings of $-1.15 a share on Nov 2, 2026, missing the $-1.06 consensus estimate by 8.5%. Revenue was $12.7M against a $16.6M estimate.
CRISPR Therapeutics delivered a double miss in the third quarter of 2026, falling short of Wall Street expectations on both the top and bottom lines as rising pipeline costs weighed on results. The company posted GAAP EPS of $-1.15, missing the $-1.06 consensus by 8.49%; that figure includes an $11.70 million acquired in-process R&D charge tied to a development milestone under the Sirius Therapeutics agreement. Revenue came in at $12.67 million, trailing the $16.56 million estimate by 23.52%, though the year-over-year comparison tells a more constructive story, with revenue up 1,325.1% from a near-zero base a quarter ago as collaboration income from CASGEVY began flowing through. The CRISPR/Cas9 gene therapy generated $99.00 million in total sales, up 30% sequentially, with the company noting that twice as many patients were treated in the first nine months of 2026 as in all of 2025. Looking ahead, investors will focus on Phase 1b data for CTX310 in severe hypertriglyceridemia, set for a late-breaking presentation at AHA Scientific Sessions on November 9, as the next potential catalyst for the stock, which analysts currently rate a consensus Buy.
- CASGEVY revenue of $99 million, up 30% quarter-over-quarter and nearly six times Q3 2025
- More than 750 patients have initiated CASGEVY treatment worldwide
- Collaboration revenue of $12.3 million vs none in prior-year quarter
- Collaboration expense, net, decreased to $41.3 million from $57.1 million due to increased share of CASGEVY revenue
- R&D expense increased to $71.9 million from $58.9 million on higher external R&D and sublicense fees
- Acquired IPR&D of $11.7 million primarily for a Sirius Agreement development milestone
“The third quarter marked meaningful progress for CRISPR Therapeutics. CASGEVY is reaching more patients, including younger children following new approvals in the U.K. and the Middle East, and the FDA's RMAT designations for CTX310 underscore its potential to address significant unmet needs in cardiovascular disease.”
CRISPR Therapeutics CEO, on the earnings call
What Is CRISPR Therapeutics's Outlook?
Upcoming catalysts disclosed by the company: - **CTX310:** Phase 1b data in severe hypertriglyceridemia will be presented in a late-breaking oral presentation at AHA Scientific Sessions 2026 on November 9, 2026. - **Zugo-cel (autoimmune):** Phase 1 data in refractory systemic sclerosis will be presented at ACR Convergence 2026 on November 8. - **CTX611:** A Phase 2 update in total knee arthroplasty is expected in the second half of 2026. CRISPR will lead global Phase 3 development. - **Zugo-cel (B-cell malignancies):** Updates are anticipated in the second half of 2026. - **siRNA collaboration:** An update on nominating up to two additional siRNA targets is expected in 2027. - **Earlier-stage programs:** CTX213 is progressing toward the clinic. CTX321 and the in vivo CAR-T programs are in IND/CTA-enabling studies.
CRSP YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $12.7M | $889,003 | +1,325.1% |
| Operating Income | −$130.0M | −$128.1M | +1.5% |
| Net Income | −$111.4M | −$116.9M | −4.7% |
CRSP Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.